Abeona Therapeutics has activated Children’s Hospital Colorado as a qualified treatment center for Zevaskyn (prademagene zamikeracel), the first FDA-approved autologous gene‑modified cellular sheet therapy for treating wounds in adults and children with recessive dystrophic epidermolysis bullosa. The Aurora-based pediatric center has completed site start-up and is moving into patient identification and scheduling, expanding the therapy’s reach through a growing network of epidermolysis bullosa centers.
The strategic signal is clear: in complex, procedure-dependent gene therapies, market access hinges less on field force scale than on site enablement, surgical logistics, and supply chain precision. The central question is whether Abeona can build and sustain a distributed network of high-performing centers quickly enough to convert latent demand, while differentiating Zevaskyn’s one-time surgical approach against alternative modalities in dystrophic EB.
This matters immediately for patients and families in the Mountain West by reducing travel burden and accelerating time to treatment. For clinicians, center activation tightens standardization around wound selection, perioperative care, and post-application follow-up. For payers, concentrated sites of excellence can enhance quality and predictability but also concentrate high-cost episodes of care. Budget impact should remain contained given the ultra-rare population, yet coverage policies will scrutinize durability, health-related quality-of-life improvement, infection and hospitalization reductions, and the operational readiness of sites to deliver consistent outcomes.
Commercial teams will recognize a familiar playbook from CAR-T and other advanced therapies: the gating factors are slot availability, operating room time, and coordination across manufacturing, shipping, and surgical teams. Abeona’s cGMP facility in Cleveland provides vertical integration that can be a competitive advantage if it translates into reliable lead times and capacity. Support programs that address travel and logistics will help, but coding, site-of-care economics, and payer policy formation for a surgical gene therapy are the real levers. Outcomes-based constructs could emerge if health plans push to align payment with sustained wound closure and pain reduction.
Medical Affairs will carry a disproportionate load. Long-term safety surveillance, registries, and real-world evidence on durability and functional benefits will shape clinical confidence and payer coverage. Education on patient selection, mapping of target wounds, and management of perioperative and post-procedural care will be essential to minimize variability. Evidence that links wound healing to downstream reductions in infections, procedures, and caregiver burden will matter as much as traditional efficacy endpoints.
Competitively, dystrophic EB is now a multi-modal market. Topical, repeat-dose gene therapies have established precedent, while Zevaskyn offers a single surgical application targeting chronic, recalcitrant wounds. The market is likely to segment by wound characteristics, care setting, and patient preference, with centers of excellence defining treatment algorithms. The broader trend is unmistakable: advanced therapies are shifting commercialization from broad prescriber engagement to high-touch orchestration at specialized sites, where operational execution becomes the brand’s moat.
Over the next year, watch the cadence of qualified treatment center activations, manufacturing turnaround times, payer policies for site-of-care reimbursement, and the conversion of known patient backlogs. Real-world comparisons between single-application surgical gene therapy and repeat topical approaches will inform therapy sequencing and coverage. The competitive edge will go to the player that can pair durable clinical performance with frictionless site operations—can Abeona scale that experience fast enough to set the standard of care in dystrophic EB?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
